Scientists develop targeted cancer treatment using nanomaterials

August 19th, 2009 in Nanotechnology / Bio & Medicine

Above: X-ray fluorescent imaging of the TiO2-mAb binding to the single brain cancer cells. The bare titianium dioxide nanoparticle bonds with an antibody and attaches itself to brain cancer cells. When exposed to concentrated white light, the titanium dioxide creates free radicals of oxygen that cause the cancer cells to die.

Above: X-ray fluorescent imaging of the TiO2-mAb binding to the single brain cancer cells. The bare titianium dioxide nanoparticle bonds with an antibody and attaches itself to brain cancer cells. When exposed to concentrated white light, the titanium dioxide creates free radicals of oxygen that cause the cancer cells to die.

(PhysOrg.com) -- Scientists from the U.S. Department of Energy's Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

Thousands of people die from malignant brain tumors every year, and the tumors are resistant to conventional therapies. This nano-bio technology may eventually provide an alternative form of therapy that targets only cancer cells and does not affect normal living tissue.

"It is a real example of how nano and biological interfacing can be used for biomedical application," said scientist Elena Rozhkova with Argonne's Center for Nanoscale Materials. "We chose brain cancer because of its difficulty in treatment and its unique receptors."

This new therapy relies on a two-pronged approach. Titanium dioxide is a versatile photoreactive nanomaterial that can be bonded with biomolecules. When linked to an antibody nanoparticles recognize and bind specifically to cancer cells. Focused visible light is shined onto the affected region, and the localized titanium dioxide reacts to the light by creating free oxygen radicals that interact with the mitochondria in the cancer cells. Mitochondria act as cellular energy plants, and when free radicals interfere with their biochemical pathways, mitochondria receive a signal to start cell death.

"The significance of this work lies in our ability to effectively target nanoparticles to specific cell surface receptors expressed on brain cancer cells," said Dr. Maciej S. Lesniak, Director of Neurosurgical Oncology at University of Chicago Brain Tumor Center. "In so doing, we have overcome a major limitation involving the application of nanoparticles in medicine, namely the potential of these agents to distribute throughout the body. We are now in a position to develop this exciting technology in preclinical models of brain tumors, with the hope of one day employing this new technology in patients."

X-ray fluorescence microscopy done at Argonne's Advanced Photon Source also showed that the tumors' invadopodia, actin-rich micron scale protrusions that allow the cancer to invade surrounding healthy cells, can be also attacked by the titanium dioxide.

So far, tests have been done only on cells in a laboratory setting, but animal testing is planned for the next phase. Results show an almost 100 percent cancer cell toxicity rate after six hours of illumination, and 80 percent after 48 hours.

Also, since the antibody only targets the cancer cells, surrounding healthy cells are not affected, unlike other cancer treatments such as chemotherapy and radiotherapy.
Rozhkova said that a proof of concept is demonstrated, and other cancers can be treated as well using different targeting molecules, but research is in the early stages.

More information: This work is published in a Nano Letters and is available online at http://pubs.acs.org/doi/full/10.1021/nl901610f .